The Technical Scientific Commission (CTS) of AIFA, in the meeting of 22 December 2021, approved the use of the Nuvaxovid (Novavax) vaccine, making it available in the entire indication authorized by EMA for subjects aged 18 or over. Vaccination involves a primary vaccination course of two doses three weeks apart.
The available data, notes the CTS, on the Nuvaxovid vaccine have shown an efficacy of about 90% in preventing symptomatic COVID-19 disease even in the population over the age of 64. The safety profile was positive, with mainly local adverse reactions.